Creative Biolabs is dedicated to providing exclusive B cell engineering service for anti-germ cell tumor delivery to facilitate your project's success.
Germ cell tumor (GCT) is one of the most common solid malignancies with a remarkable 5-year survival rate of approximately 95%, affecting young men between the ages of 20 and 40 years. The global incidence of germ cell tumors has been increasing over the past few decades. A variety of cancer treatment approaches including surgery, chemotherapy, radiotherapy, and target therapies have been studied in high cure rates in patients with metastatic disease.
Fig.1 The rationale of germ cell tumor. (Creative Biolabs)
Monoclonal antibody target to germ cell tumor is a rapidly developing class of GCTs therapeutic drugs, but a major limitation associated with this treatment is the need for repeated administration, often over years or decades, which usually involves intravenous infusion in ambulatory care centers. To avoid the need for repeated administration of Abs, genetically engineered B cells open up a new avenue to use B cells to treat disease. Powered by our strong expertise in cell engineering, Creative Biolabs provides comprehensive B cell engineering service for anti-germ cell tumor antibody delivery.
Fig.2 The main experimental diagram related to
B cells service. (Creative Biolabs)
For more details about our B cell engineering service for anti-sarcoma antibody delivery, please don't hesitate to contact us for more information.